Maxim Group analyst Anthony Vendetti maintained a Buy rating on Sientra (SIEN) today and set a price target of $16. The company’s shares closed yesterday at $8.27, close to its 52-week low of $7.10.
Vendetti commented:
“Market close, SIEN reported 1Q19 revenue inline with both Maxim and consensus estimates, but missed EPS on a GAAP basis. Breast Products revenue rose 14% y/y and miraDry sales +27% y/y. We expect both product lines to ramp up significantly in 2H19. Additionally, Sientra gained approval from the FDA for its extra-high profile reconstruction implants. Management introduced revenue guidance for 2019, with total revenue of $79M-$83M, below our prior estimate of $85.7M. We are reducing our PT to $16, from $20, due to lower estimates and expected share dilution.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 4.4% and a 49.3% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sientra with a $18 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.79 and a one-year low of $7.10. Currently, Sientra has an average volume of 866.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry.
